Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 119.22 +1.44 (1.22%)
price chart
Johnson & Johnson Prostate Cancer Drug Impresses
A new study shows that Johnson & Johnson's prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy.
Johnson & Johnson Latest Company To Break Away From ALEC
Johnson & Johnson is the latest company to break away from the American Legislative Exchange Council (ALEC). On June 12, Johnson & Johnson announced it would stop funding the group that has pushed states to pass voter ID and stand-your-ground ...
Johnson & Johnson Should Split Up Says Goldman
By Peter Loftus. Johnson & Johnson should split into three companies, which could value health-care conglomerate at $76 a share, up more than 20% from current price of $62, Goldman Sachs says.
Cramer: Johnson & Johnson Could Unlock Value by Splitting Up
Take Johnson & Johnson, for example. The New Brunswick, N.J.-based company makes everything from Band-Aids and Tylenol to knee implants and prescription drugs, all of which are fairly resistant to a global slowdown, Cramer said.
Johnson & Johnson's Synthes Deal Revives Foreign Tax Debate
To make the largest deal in its 126-year history an earnings boost, Johnson & Johnson (JNJ) is keeping its acquisition of Synthes as far as from the U.S.
Johnson & Johnson Announces Completion of Synthes Acquisition  PR Newswire (press release)
Johnson & Johnson completes $20B takeover of Synthes  Bizjournals.com
BREAKING: Johnson & Johnson Drops ALEC
Pharmaceutical giant Johnson and Johnson announced today that they are dropping their membership from the American Legislative Exchange Council (ALEC).
Johnson & Johnson diabetes drug tops older therapies in studies
An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co's Januvia and an older common treatment, glimepiride, according to data from a pair of late stage clinical trials.
Johnson & Johnson Unit to Halt Urinary Implants
Johnson & Johnson's Ethicon division will stop selling four types of mesh implants used to treat urinary incontinence, the company announced in a letter to judges overseeing two large groups of lawsuits filed by women who claim the devices caused ...
Johnson & Johnson to stop selling surgical mesh  Fox News
J&J Tells Judge It Will Stop Sales of Vaginal Implants  Bloomberg
Baby Soaps and Shampoos Trigger Positive Marijuana Tests
Commonly used baby soaps and shampoos, including products from Johnson & Johnson, Aveeno and CVS, can trigger a positive result on newborns' marijuana screening tests, according to a recent study.
Johnson & Johnson's Favorable Ratings: Does The Market Prefer Trademarks Or ...
Analysts are starting to like Johnson & Johnson again. (Disclaimer: I have now exhausted my knowledge of markets.) What drives the value of companies these days, brand power (trademarks) or brain power (patents)?